Department of Anesthesiology and Pain Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Department of Anesthesiology and Pain Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Pain Physician. 2020 Aug;23(4S):S283-S294.
The suppression of hypothalamic-pituitary-adrenal (HPA) axis is a common complication associated with epidural steroid injections (ESIs). However, the effect of different doses is unknown.
The primary objective was to compare the differences in the duration of HPA suppression following treatment with different doses of ESI; triamcinolone acetate (TA) 40 mg and TA 20 mg. The secondary objectives were to compare the extent of salivary cortisol (SC) reduction, the incidence of adrenal insufficiency (AI), and the differences in a numeric rating scale (NRS) depending on the varying levels of TA dose used for ESI.
A double-blind, parallel-group, randomized controlled trial.
Pain clinics in a university hospital.
The patients were treated with TA epidurally and divided into 2 groups (T20 and T40) depending on the dose of TA (20 mg and 40 mg). The SC concentration was measured before and after ESI to calculate the duration of HPA axis suppression, the extent of SC concentration reduction, and the SC recovery rate. Additionally, NRS and adrenocorticotropic hormone stimulation tests were used.
Thirty patients were analyzed. The T40 group showed longer HPA suppression (19.7 ± 3.1 days) compared with that of the T20 group (8.0 ± 2.4 days). The recovery rate of the T40 group was lower than that of the T20 group (P < 0.015). However, there was no difference in the extent of reduction in SC concentration after ESI, the occurrence of AI, and pain reduction.
There were selection bias and no placebo control.
Although the difference in pain relief according to the ESI dose is not significant, the HPA suppression is prolonged with a higher dose than a lower dose, and the recovery is slower. Therefore, the time interval between consecutive ESIs should be adjusted depending on the steroid dose to ameliorate the adverse effects of steroids.
硬膜外注射(ESI)后抑制下丘脑-垂体-肾上腺(HPA)轴是一种常见的并发症。然而,不同剂量的效果尚不清楚。
比较不同剂量的曲安奈德(TA)40mg 和 TA 20mg 治疗后 HPA 抑制持续时间的差异,这是主要目标;比较唾液皮质醇(SC)浓度降低的程度、肾上腺功能不全(AI)的发生率以及根据不同 TA 剂量使用 ESI 时数字评定量表(NRS)的差异,这是次要目标。
一项双盲、平行组、随机对照试验。
在一所大学医院的疼痛诊所。
患者接受 TA 硬膜外治疗,并根据 TA 剂量(20mg 和 40mg)分为 2 组(T20 和 T40)。在 ESI 前后测量 SC 浓度,以计算 HPA 轴抑制持续时间、SC 浓度降低程度和 SC 恢复率。此外,还使用了 NRS 和促肾上腺皮质激素刺激试验。
对 30 名患者进行了分析。T40 组 HPA 抑制时间(19.7 ± 3.1 天)明显长于 T20 组(8.0 ± 2.4 天)。T40 组的恢复率低于 T20 组(P < 0.015)。然而,ESI 后 SC 浓度降低程度、AI 发生率和疼痛减轻程度没有差异。
存在选择偏倚和无安慰剂对照。
虽然根据 ESI 剂量缓解疼痛的差异不显著,但高剂量比低剂量抑制 HPA 的时间更长,恢复速度更慢。因此,为了减轻类固醇的不良反应,应根据类固醇剂量调整连续 ESI 之间的时间间隔。